Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
10 results
  • Hematology

18-503          Phase I

A Phase 1 Safety, Tolerability, and Pharmacokinetics & Pharmacodynamics Study of Multiple-Dose BIVV009 in Patients With Chronic Immune Thrombocytopenia (ITP) (View details on clinicaltrial.gov)

  • Hematology

19-292          Phase III

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (View details on clinicaltrial.gov)

  • Hematology

18-162          Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Subjects With Pyruvate Kinase Deficiency (View details on clinicaltrial.gov)

  • Hematology

18-087          Phase III

A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of BIVV009 in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion (View details on clinicaltrial.gov)

  • Hematology

19-148          Phase III

A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Active Non-Hematological Cancers (View details on clinicaltrial.gov)

  • Hematology

18-048          Phase II

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura (View details on clinicaltrial.gov)

  • Hematology

18-074          Phase III

ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX (View details on clinicaltrial.gov)

  • Hematology

19-274          Phase III

ATLAS-OLE: An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX (View details on clinicaltrial.gov)

Showing 1 - 10 of 10 results